WASHINGTON — The Affordable Care Act torqued the statute on qui tam lawsuits in important ways, which is one of several factors that have placed substantially greater influence in the hands of agencies other than FDA over FDA-regulated communication. However, Jennifer Bragg, a partner at Skadden, Arps, Slate, Meagher & Flom (New York) told an audience here in the nation's capital that FDA is paying far more attention to such issues for a number of reasons, and thus, "I believe FDA has reclaimed its role of the leading arbiter of policy" in this area.